Rhabdomyosarcoma staging: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}};{{AE}} {{S.M}} | {{CMG}};{{AE}} {{S.M}} | ||
==Overview== | ==Overview== | ||
There are two [[Cancer staging|staging]] [[classification]] for [[rhabdomyosarcoma]] including Children group (CG) and [[tumor]], [[Node (physics)|node]], and [[metastasis]] system (TNM). Each of them has four stages of [[rhabdomyosarcoma]] based on the location of [[tumor]], size of [[tumor]], involvement of [[lymph nodes]], and [[metastasis]]. Also, [[Risk Stratification Tools|risk]] [[stratification]] [[system]] is used for [[classification]] of [[patients]] into low, intermediate, and high risk groups. | |||
==Staging of rhabdomyosarcoma== | ==Staging of rhabdomyosarcoma== | ||
* There are two staging classification for rhabdomyosarcoma:<ref name="pmid2407808">{{cite journal| author=Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann F, Webber B et al.| title=Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. | journal=J Clin Oncol | year= 1990 | volume= 8 | issue= 3 | pages= 443-52 | pmid=2407808 | doi=10.1200/JCO.1990.8.3.443 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2407808 }} </ref> | * There are two [[Cancer staging|staging]] [[classification]] for [[rhabdomyosarcoma]]:<ref name="pmid2407808">{{cite journal| author=Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann F, Webber B et al.| title=Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. | journal=J Clin Oncol | year= 1990 | volume= 8 | issue= 3 | pages= 443-52 | pmid=2407808 | doi=10.1200/JCO.1990.8.3.443 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2407808 }} </ref> | ||
** Clinical group (CG) | ** Clinical group (CG) | ||
*** Created by intergroup rhabdomyosarcoma study group (IRSG) in 1972. | *** Created by intergroup rhabdomyosarcoma study group (IRSG) in 1972. | ||
*** Based on spread of tumor cells at diagnosis and remaining disease after surgery. | *** Based on spread of [[tumor]] [[Cells (biology)|cells]] at [[diagnosis]] and remaining [[disease]] after [[surgery]]. | ||
*** Categorized in four groups. | *** Categorized in four groups. | ||
** Tumor, node, metastasis system (TNM) | ** [[Tumor]], node, and [[metastasis]] [[system]] (TNM) | ||
*** Based on tumor size, node involvement, and metastases. | *** Based on [[tumor]] size, node involvement, and [[metastases]]. | ||
***Categorized in four groups. | ***Categorized in four groups. | ||
{| class="wikitable" | {| class="wikitable" | ||
Line 23: | Line 23: | ||
* Contain 13% of all cases | * Contain 13% of all cases | ||
* Localized region | * Localized region | ||
* Complete resection | * Complete [[resection]] | ||
* No nodal involvement | * No nodal involvement | ||
|- | |- | ||
Line 29: | Line 29: | ||
| style="background:#F5F5F5;" + | | | style="background:#F5F5F5;" + | | ||
* Contain 20% of all cases | * Contain 20% of all cases | ||
* IIA group: Complete resection with microscopic residual disease/ no nodal involvement | * IIA group: Complete [[resection]] with [[microscopic]] [[residual]] [[disease]]/ no nodal involvement | ||
* IIB group: Complete resection with no microscopic residual diseases/ regional nodal involvement | * IIB group: Complete resection with no microscopic residual diseases/ regional nodal involvement | ||
* IIC group: Complete resection with microscopic residual disease/ regional nodal involvement | * IIC group: Complete resection with microscopic residual disease/ regional nodal involvement |
Revision as of 15:18, 8 March 2019
Rhabdomyosarcoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Rhabdomyosarcoma staging On the Web |
American Roentgen Ray Society Images of Rhabdomyosarcoma staging |
Risk calculators and risk factors for Rhabdomyosarcoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
Overview
There are two staging classification for rhabdomyosarcoma including Children group (CG) and tumor, node, and metastasis system (TNM). Each of them has four stages of rhabdomyosarcoma based on the location of tumor, size of tumor, involvement of lymph nodes, and metastasis. Also, risk stratification system is used for classification of patients into low, intermediate, and high risk groups.
Staging of rhabdomyosarcoma
- There are two staging classification for rhabdomyosarcoma:[1]
- Clinical group (CG)
- Tumor, node, and metastasis system (TNM)
- Based on tumor size, node involvement, and metastases.
- Categorized in four groups.
Group | Description |
---|---|
I |
|
II |
|
III |
|
IV |
|
Stage | Description |
---|---|
1 |
|
2 |
|
3 |
|
4 |
|
Risk type | Description |
---|---|
Low |
|
Intermediate |
|
High |
|
References
- ↑ Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann F, Webber B; et al. (1990). "Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee". J Clin Oncol. 8 (3): 443–52. doi:10.1200/JCO.1990.8.3.443. PMID 2407808.
- ↑ Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C; et al. (1995). "The Third Intergroup Rhabdomyosarcoma Study". J Clin Oncol. 13 (3): 610–30. doi:10.1200/JCO.1995.13.3.610. PMID 7884423.
- ↑ Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB; et al. (2001). "Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease". J Clin Oncol. 19 (12): 3091–102. doi:10.1200/JCO.2001.19.12.3091. PMID 11408506.
- ↑ Dasgupta R, Fuchs J, Rodeberg D (2016). "Rhabdomyosarcoma". Semin Pediatr Surg. 25 (5): 276–283. doi:10.1053/j.sempedsurg.2016.09.011. PMID 27955730.
- ↑ Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ; et al. (2001). "Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V." J Pediatr Hematol Oncol. 23 (4): 215–20. PMID 11846299.